CURIUM JOIN FORCES WITH PEPTIDREAM FOR PROSTATE CANCER THERANOSTICS IN JAPAN

KUALA LUMPUR, Oct 2 (Bernama) -- Curium, a world leader in nuclear medicine, has entered into a strategic partnership with PDRadiopharma Inc, a wholly-owned subsidiary of PeptiDream, for the clinical development, regulatory filing, and commercialisation in Japan of two agents, 177Lu-PSMA-I&T and 64Cu-PSMA-I&T.

Curium will continue to lead global development of the two agents and support PDRadiopharma through technology transfer to support the set-up of manufacturing lines in Japan, including a high throughput Copper 64 manufacturing line based on Curium’s proprietary technology.

According to a statement, Curium and PDRadiopharma have a long-standing relationship in the radiopharmaceutical field.

“As a global innovator in the field of radiopharmaceuticals with a promising late-stage oncology pipeline, Curium is delighted to partner with PDRadiopharma, which has more than four decades of experience in Japan.

“Curium and PDRadiopharma plan to leverage their complementary strengths to accelerate the development of innovative products for the benefit of prostate cancer patients in Japan,” said Curium Chief Executive Officer, International Markets, Chaitanya Tatineni.

The two agents target prostate specific membrane antigen (PSMA) expressed on prostate cancer cells and are being investigated for prostate cancer treatment and diagnostics.

Both target tumours with high levels of PSMA expression, thus potentially forming a theranostic (therapeutic & diagnostic) pair.

PSMA-targeted PET/CT imaging is increasingly emerging as a highly sensitive method for detection of locally recurrent or metastatic lesions in the context of biochemical recurrence and for localisation of primary prostate cancer.

Prostate cancer continues to be widely prevalent in Japan. Annually, there are approximately 90,000 to 100,000 new cases, with patients with metastatic castration-resistant prostate cancer having an overall survival rate of approximately three years in clinical trial settings and even shorter in the real world, and there remains a significant unmet medical need for therapies.

-- BERNAMA